stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Current ratio
MBX Biosciences, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 18.1×, down 6.5× from fiscal 2025 (24.6×). That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 24.6× | 1.81% |
| FY2024 | 24.2× | 13.77% |
| FY2023 | 21.3× | 64.99% |
| FY2022 | 12.9× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 18.1× | (41.27%) |
| Mar 2026 | 30.8× | 25.05% |
| Dec 2025 | 24.6× | (25.28%) |
| Sep 2025 | 33.0× | 69.04% |
| 5 more quarters | Free account |
Current ratio against peers
| Company | Current ratio |
|---|---|
| MBX MBX Biosciences, Inc. | 18.1× |
| PHVS Pharvaris N.V. compare | 11.9× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 11.8× |
| XNCR Xencor, Inc. compare | 6.4× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 5.0× |
| RCUS Arcus Biosciences, Inc. compare | 3.3× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)